We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Roche Holdings Ltd AG (QX) | USOTC:RHHBY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.07 | -0.23% | 29.75 | 29.55 | 30.50 | 30.05 | 29.53 | 29.80 | 5,444,214 | 21:57:01 |
By Stephen Nakrosis
Genentech on Monday said the U.S. Food and Drug Administration approved its Tecentriq to treat certain patients with metastatic non-small cell lung cancer.
The company said the approval of Tecentriq, or atezolizumab, was based on an interim analysis of its Phase III IMpower110 study "showing Tecentriq demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy."
Genentech also said the latest approval was "Tecentriq's fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall."
Tecentriq is the only single-agent cancer immunotherapy with three dosing options, Genentech said.
The company "has an extensive development program for Tecentriq, including multiple ongoing and planned Phase III studies across lung, genitourinary, skin, breast, gastrointestinal, gynecological and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines," it said.
Genentech is a member of the Roche Group.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 18, 2020 16:17 ET (20:17 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Roche (QX) Chart |
1 Month Roche (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions